## M Catherine Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7269082/publications.pdf

Version: 2024-02-01

47 papers

382 citations

949033 11 h-index 939365 18 g-index

47 all docs

47 docs citations

47 times ranked

779 citing authors

#	Article	IF	CITATIONS
1	Childhood head trauma and the risk of childhood brain tumours: A caseâ€control study in Ontario, Canada. International Journal of Cancer, 2022, 150, 795-801.	2.3	1
2	Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 679-687.	1.1	1
3	The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients. Lung Cancer, 2021, 152, 58-65.	0.9	22
4	The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. Quality of Life Research, 2021, 30, 445-454.	1.5	6
5	Internet and social media use in cancer patients: association with distress and perceived benefits and limitations. Supportive Care in Cancer, 2021, 29, 5273-5281.	1.0	16
6	Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical Lung Cancer, 2021, 22, 390-407.	1.1	7
7	Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. Clinical Lung Cancer, 2021, , .	1.1	1
8	Association of gastro-oesophageal reflux disease and quality of life in patients with chronic rhinosinusitis. Acta Otorhinolaryngologica Italica, 2021, 41, 450-460.	0.7	3
9	Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study. Lung Cancer, 2020, 147, 1-11.	0.9	6
10	Cancer Patient-Reported Preferences and Knowledge for Liquid Biopsies and Blood Biomarkers at a Comprehensive Cancer Center. Cancer Management and Research, 2020, Volume 12, 1163-1173.	0.9	2
11	Health-related social media use and preferences of adolescent and young adult cancer patients for virtual programming. Supportive Care in Cancer, 2020, 28, 4789-4801.	1.0	14
12	The impact of tobacco retail density on overall survival (OS) in lung cancer survivors Journal of Clinical Oncology, 2020, 38, 12058-12058.	0.8	1
13	Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts) with metastatic esophageal cancer Journal of Clinical Oncology, 2020, 38, 4544-4544.	0.8	1
14	Blood-based-inflammation-markers, body mass index, and survival of nonmetastatic esophageal cancer Journal of Clinical Oncology, 2020, 38, 324-324.	0.8	0
15	Development and prospective evaluation of CAPLET, a cancer ambulatory patient physical function longitudinal evaluation tool for routine clinical practice. Supportive Care in Cancer, 2019, 27, 521-530.	1.0	3
16	Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience. Oncologist, 2019, 24, e1219-e1227.	1.9	14
17	Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium. Journal of Thoracic Oncology, 2019, 14, 1594-1607.	0.5	81
18	Association of two <i>BRM</i> promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. Molecular Carcinogenesis, 2019, 58, 1960-1973.	1.3	1

#	Article	IF	Citations
19	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1228-1237.	1.1	11
20	Realâ€world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 7542-7555.	1.3	14
21	Increasing Access to Developmental Services for Children with Autism Spectrum Disorder: The Pediatric Developmental Passport Pilot Randomized Trial. Journal of Autism and Developmental Disorders, 2019, 49, 4867-4876.	1.7	5
22	The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist, 2019, 24, e501-e509.	1.9	8
23	Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors Journal of Clinical Oncology, 2019, 37, 11559-11559.	0.8	1
24	Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI) Journal of Clinical Oncology, 2019, 37, e20667-e20667.	0.8	1
25	The Esophageal Online Patient Reported Outcomes (EsO-PRO) Questionnaire: Formal implementation and assessment of a combined clinical and research data collection tool Journal of Clinical Oncology, 2019, 37, 37-37.	0.8	О
26	Does ethnicity affect the relationship between body mass index (BMI) and overall survival (OS) in non-small cell lung cancer (NSCLC)? A pooled analysis of 17,326 International Lung Cancer Consortium (ILCCO) patients (pts) Journal of Clinical Oncology, 2019, 37, 1562-1562.	0.8	0
27	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors Journal of Clinical Oncology, 2019, 37, e20594-e20594.	0.8	0
28	Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors Journal of Clinical Oncology, 2019, 37, 11561-11561.	0.8	0
29	Barriers and facilitators to the implementation of routine ototoxicity screening for head and neck cancer patients Journal of Clinical Oncology, 2019, 37, 127-127.	0.8	1
30	Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations Journal of Clinical Oncology, 2019, 37, 102-102.	0.8	0
31	Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors Journal of Clinical Oncology, 2019, 37, 141-141.	0.8	1
32	Routine Edmonton Symptom Assessment System (ESAS) scores in epithelioid malignant pleural mesothelioma (eMPM) patients undergoing palliative systemic therapy Journal of Clinical Oncology, 2019, 37, 96-96.	0.8	0
33	Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants Journal of Clinical Oncology, 2018, 36, 6048-6048.	0.8	1
34	Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre Journal of Clinical Oncology, 2018, 36, 6587-6587.	0.8	0
35	The influence of patient-reported adverse events on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology, 2018, 36, 185-185.	0.8	0
36	Routine collection of EQ-5D-5L derived utility scores in a brain metastases clinic: Correlation with health-related quality of life (FACT-Br) Journal of Clinical Oncology, 2018, 36, 200-200.	0.8	1

#	Article	IF	CITATIONS
37	Comparison of health utility values from EQ-5D-3L and EQ-5D-5L in patients with breast cancer in different health states Journal of Clinical Oncology, 2018, 36, 197-197.	0.8	O
38	Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. Clinical Lung Cancer, 2017, 18, 388-395.e4.	1.1	23
39	Body mass index and prognosis in patients with head and neck cancer. Head and Neck, 2017, 39, 1226-1233.	0.9	64
40	EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre. Patient, 2017, 10, 105-115.	1.1	23
41	Lifestyle Behaviors in Elderly Cancer Survivors: A Comparison With Middle-Age Cancer Survivors. Journal of Oncology Practice, 2015, 11, e450-e459.	2.5	27
42	Association between polymorphisms of the FOXF1 and MHC locus genes and gastroesophageal reflux disease (GERD) Journal of Clinical Oncology, 2014, 32, 15-15.	0.8	2
43	Perceptions of benefits and harms of alcohol consumption as predictors of alcohol cessation in adult cancer survivors Journal of Clinical Oncology, 2013, 31, 9595-9595.	0.8	O
44	The role of social exposure to smoking on smoking cessation in adult cancer survivors Journal of Clinical Oncology, 2013, 31, 9536-9536.	0.8	0
45	Comparing elderly and non-elderly adult cancer survivors: Differences in modifiable behaviours of smoking and alcohol cessation and physical activity Journal of Clinical Oncology, 2013, 31, 9551-9551.	0.8	O
46	Willingness of patients to provide biologic samples for pharmacogenomic testing Journal of Clinical Oncology, 2013, 31, 6543-6543.	0.8	1
47	Absence of germline and somatic p53 alterations in children with sporadic brain tumors. Journal of Neuro-Oncology, 2001, 52, 227-235.	1.4	18